EUVIMEDEUVIMED entdecken
Crossref

The impact of survivorship care on burden of disease among Hodgkin lymphoma survivors

Eline M J Lammers iD, Josée M Zijlstra, Michael Schaapveld iD, Juanita A Haagsma, Cécile P M Janus, Karin M Aarsman, Liane C J Te Boome, Maaike M G Schippers, Rinske S Boersma, Saskia E Rademakers iD, Wouter J Plattel, Lara H Böhmer und 8 weitere

JNCI: Journal of the National Cancer Institute · 01.08.2026 · 118 (8) · 1514-1526

DOI: 10.1093/jnci/djag080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 11.04.2026. Verfasst von Eline M J Lammers und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Hodgkin Disease, Cancer Survivors, Survivorship, Cost of Illness. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Netherlands Organization for Health Research and Development, Dutch Cancer Society, Dutch Ministry of Health, Welfare and Sport.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hodgkin lymphoma (HL) survivors are at increased risk of late adverse events, eg, cardiovascular diseases (CVD), breast cancer (BC), hypothyroidism and severe infections. At Dutch BETER clinics, HL survivors are regularly screened for (risk factors for) these adverse events. The impact of survivorship care on the burden of disease from adverse outcomes has rarely been evaluated.

Methods

In a nationwide retrospective cohort study, we compared HL survivors invited for BETER care in 2013-2016 (intervention group) with matched survivors who were eligible for such care but were not invited until 2019-2024 (comparison group). Incidence and mortality rates for CVD, BC, hypothyroidism, and severe infections were collected from general practitioners and nationwide registries. Disability-adjusted life years (DALYs) attributable to late adverse events were compared using multivariable regression models.

Results

At study start, survivors in the intervention group (n = 491) and comparison group (n = 373) had a median age of 46 years; median time since HL diagnosis was 15-18 years. After 8.5 years (median), there were no significant differences in DALYs attributable to CVD, BC, hypothyroidism, and severe infections between the groups. In both groups, approximately one third of survivors acquired DALYs attributable to adverse events. Adherence to recommended screening diagnostics was high, but cardiovascular risk management and vaccination rates were suboptimal.

Conclusion

After 8.5 years of follow-up, survivorship care for HL survivors was not associated with lower disease burden. Better care coordination, amendment of the cardiovascular risk management guidelines, and greater survivor involvement may improve long-term effectiveness of measures to prevent late adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseCancer SurvivorsSurvivorshipCost of IllnessHumansFemaleMiddle AgedRetrospective StudiesAdultCardiovascular DiseasesMaleNetherlandsHypothyroidismQuality-Adjusted Life YearsRisk FactorsBreast NeoplasmsIncidence

Autor:innen und Institutionen

  • Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Hematology, Amsterdam UMC, Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Radiation Oncology, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Department of Hematology, Haaglanden Medical Center, Leidschendam, the Netherlands.

ORCID-Profile: Eline M J Lammers, Michael Schaapveld, Saskia E Rademakers, Flora E van Leeuwen, Annelies Nijdam

Förderung

  • Netherlands Organization for Health Research and Development
  • Dutch Cancer Society
  • Dutch Ministry of Health, Welfare and Sport

Zitieren

APA

Lammers, E. M. J., Zijlstra, J. M., Schaapveld, M., Haagsma, J. A., Janus, C. P. M., Aarsman, K. M., Boome, L. C. J. T., Schippers, M. M. G., Boersma, R. S., Rademakers, S. E., Plattel, W. J., Böhmer, L. H., van Den Berg, M., Kroeze, A. C., Strobbe, L. S., Deenik, W., de Lil, H. S., Aleman, B. M. P., van Leeuwen, F. E., & Nijdam, A. (2026). The impact of survivorship care on burden of disease among Hodgkin lymphoma survivors. JNCI: Journal of the National Cancer Institute, 118(8), 1514-1526. https://doi.org/10.1093/jnci/djag080

Vancouver

Lammers EMJ, Zijlstra JM, Schaapveld M, Haagsma JA, Janus CPM, Aarsman KM, et al. The impact of survivorship care on burden of disease among Hodgkin lymphoma survivors. JNCI: Journal of the National Cancer Institute. 2026;118(8):1514-1526. doi:10.1093/jnci/djag080

BibTeX
@article{Lammers2026,
  author = {Lammers, Eline M J and Zijlstra, Josée M and Schaapveld, Michael and Haagsma, Juanita A and Janus, Cécile P M and Aarsman, Karin M and Boome, Liane C J Te and Schippers, Maaike M G and Boersma, Rinske S and Rademakers, Saskia E and Plattel, Wouter J and Böhmer, Lara H and van Den Berg, Marieke and Kroeze, Adriaantje C and Strobbe, Leonie S and Deenik, Wendy and de Lil, Heleen S and Aleman, Berthe M P and van Leeuwen, Flora E and Nijdam, Annelies},
  title = {The impact of survivorship care on burden of disease among Hodgkin lymphoma survivors},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2026},
  volume = {118},
  number = {8},
  pages = {1514--1526},
  doi = {10.1093/jnci/djag080}
}
Kostenlos starten →